Nothing said here yet.
to join the conversation.
Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited Medicilon's Nanhui R&D Center.
The path for Revolution Medicines to grow an initial investment of $25,000 into $1 million is a daunting one.
The biotech has experienced a pullback in recent weeks.
REDWOOD CITY, Calif., Oct.
Revolution Medicines has become one of the most eye-catching moves in biotech over the past few years, and the latest regulatory milestones now put a sharper spotlight on what investors are actually paying for on its balance sheet.
Revolution Medicines (RVMD) is back in focus after presenting new subgroup data from its Phase 3 RASolute 302 trial at the ESMO 2026 Congress in Madrid, highlighting overall survival outcomes with RASONQUE in metastatic pancreatic cancer.
Expanding on the unprecedented final results previously reported from the Phase 3 RASolute 302 trial, the exploratory subgroup analyses showed RASONQUE consistently provided an overall survival benefit compared with chemotherapy across key subgroups,…
Revolution Medicines Inc. (NASDAQ:RVMD) began treating patients in its global Phase 3 clinical study, RASolve 308, to evaluate a combination treatment for metastatic lung cancer.
Approval Was the First Hurdle, Not the Last Revolution Medicines, Inc. (NASDAQ:RVMD) is no longer valuing a theoretical pancreatic cancer drug.
Revolution Medicines reported that the EMA’s CHMP issued a positive opinion for RASONQUE as a monotherapy for previously treated metastatic pancreatic adenocarcinoma in adults, based on the Phase 3 RASolute 302 trial against cytotoxic chemotherapy.